Cure My Disease

Don't miss your cure!

 Log in / Sign up

Weight loss pill shows promise in major trial

NCT ID NCT05564117

Completed Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a daily 25 mg semaglutide pill in 307 adults with overweight or obesity over 64 weeks. Participants taking the drug lost more weight than those on placebo, with many achieving at least 5% body weight reduction. The pill offers a convenient alternative to injections for weight management.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
semaglutide
What this could lead to
If successful, this could provide a convenient daily pill for significant weight loss in people with overweight or obesity.
What could go wrong
This is a completed Phase 3 trial, but results may not apply to everyone. Side effects like nausea or vomiting are possible, and weight regain may occur after stopping treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY OVERWEIGHT

Contacts and locations

Locations

  • Accellacare

    Wilmington, North Carolina, 28401, United States

  • Beata Miklaszewicz&Dariusz Dabrowski "CARDIAMED" s.j.

    Legnica, Lower Silesian Voivodeship, 59-220, Poland

  • Centrum Zdrowia Metabolicznego

    Poznan, Wielkopolskie Voivodeship, 60-589, Poland

  • Diabetologische Gemeinschaftspraxis Dr. Staudenmeyer und Dr. Schiwietz

    Lingen, 49808, Germany

  • ETG Lublin

    Lublin, Lublin Voivodeship, 20-412, Poland

  • ETG Siedlce

    Siedlce, Masovian Voivodeship, 08-110, Poland

  • ETG Warszawa Sp. z o.o.

    Warsaw, Masovian Voivodeship, 02-677, Poland

  • East West Medical Research Institute_Honolulu

    Honolulu, Hawaii, 96814, United States

  • FDRC

    Costa Mesa, California, 92627, United States

  • G.A. Research Associates Ltd.

    Moncton, New Brunswick, E1G 1A7, Canada

  • Gabinet Leczenia Otylosci i Chorob Dietozaleznych

    Bialystok, Podlaskie Voivodeship, 15-281, Poland

  • InnoDiab Forschung GmbH

    Essen, 45136, Germany

  • MZM Praxis Drs. Erlinger

    Stuttgart, 70378, Germany

  • MedicalCenter am Clemenshospital - Schwerpunktpraxis für Diabetologie und Ernährungsmedizin

    Münster, 48153, Germany

  • Praxis Dr. med. Wenzl-Bauer

    Rehlingen-Siersburg, 66780, Germany

  • Praxis für Prävention und Therapie, Drs Jacob

    Villingen-Schwenningen, 78048, Germany

  • RED-Institut für medizinische Forschung und Fortbildung GmbH

    Oldenburg in Holstein, 23758, Germany

  • Selma Medical Associates

    Winchester, Virginia, 22601, United States

  • UT Southwestern Med Cntr

    Dallas, Texas, 75390-9302, United States

  • Univsty Of AL At Birmingham

    Birmingham, Alabama, 35294, United States

  • Washington Cntr Weight Mgmt

    Arlington, Virginia, 22206, United States

  • Wharton Med Clin Trials

    Hamilton, Ontario, L8L 5G8, Canada

  • Zentrum für klinische Studien Allgäu Oberschwaben

    Wangen, 88239, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.